Seminars in Hematology
Volume 46, Issue 3 , Pages 313-324 , July 2009

Infections in Pediatric Patients With Hematologic Malignancies

References 

  1. Christensen MS, Heyman M, Mottonen M, Zeller B, Jonmundsson G, Hasle H. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol. 2005;131:50–58
  2. Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548–2555
  3. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–4489
  4. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384–4393
  5. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110:3532–3539
  6. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2008;26:3971–3978
  7. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108:441–451
  8. Lausen B, Schmiegelow K, Andreassen B, Madsen HO, Garred P. Infections during induction therapy of childhood acute lymphoblastic leukemia—no association to mannose-binding lectin deficiency. Eur J Haematol. 2006;76:481–487
  9. Auletta JJ, O'Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol. 1999;21:501–508
  10. Viscoli C, Castagnola E, Giacchino M, Cesaro S, Properzi E, Tucci F, et al. Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer. 1999;35:770–774
  11. Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296–1304
  12. Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, et al. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatr Blood Cancer. 2004;43:571–579
  13. Erdur B, Yilmaz S, Oren H, Demircioglu F, Cakmakc H, Irken G. Evaluating pulmonary complications in childhood acute leukemias. J Pediatr Hematol Oncol. 2008;30:522–526
  14. Harris MB, Shuster JJ, Pullen J, Borowitz MJ, Carroll AJ, Behm FG, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group study. Leukemia. 2000;14:1570–1576
  15. Castagnola E, Caviglia I, Pistorio A, Fioredda F, Micalizzi C, Viscoli C, et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer. 2005;41:1439–1445
  16. Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group study CCG-2891. J Clin Oncol. 2000;18:1845–1855
  17. Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, Deswarte-Wallace J, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115:1100–1108
  18. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88:1964–1969
  19. Cesaro S, Chinello P, De Silvestro G, Marson P, Picco G, Varotto S, et al. Granulocyte transfusions from G-CSF-stimulated donors for the treatment of severe infections in neutropenic pediatric patients with onco-hematological diseases. Support Care Cancer. 2003;11:101–106
  20. Santolaya ME, Alvarez AM, Becker A, Cofre J, Enriquez N, O'Ryan M, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415–3421
  21. Bakhshi S, Padmanjali KS, Arya LS. Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes. Pediatr Hematol Oncol. 2008;25:385–392
  22. Jagarlamudi R, Kumar L, Kochupillai V, Kapil A, Banerjee U, Thulkar S. Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol (Northwood, London, England). 2000;17:111–116
  23. Hengartner H, Berger C, Nadal D, Niggli FK, Grotzer MA. Port-A-Cath infections in children with cancer. Eur J Cancer. 2004;40:2452–2458
  24. Adler A, Yaniv I, Solter E, Freud E, Samra Z, Stein J, et al. Catheter-associated bloodstream infections in pediatric hematology-oncology patients: factors associated with catheter removal and recurrence. J Pediatr Hematol Oncol. 2006;28:23–28
  25. Rubin LG, Shih S, Shende A, Karayalcin G, Lanzkowsky P. Cure of implantable venous port-associated bloodstream infections in pediatric hematology-oncology patients without catheter removal. Clin Infect Dis. 1999;29:102–105
  26. Vuong C, Otto M. Staphylococcus epidermidis infections. Microbes Infect Inst Pasteur. 2002;4:481–489
  27. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31
  28. Feusner J, Alonzo T, Dinndorf P, et al. Infectious complications of intensive chemotherapy on Childrens' Cancer Group protocol CCG-2961 for pediatric acute myeloid leukemia. [abstract 1287] Blood. 2002;100:332a
  29. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82:2275–2281
  30. Rossetti F, Cesaro S, Putti MC, Zanesco L. High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol. 1995;12:387–392
  31. Sotiropoulos SV, Jackson MA, Woods GM, Hicks RA, Cullen J, Freeman AI. Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J. 1989;8:755–758
  32. Reilly AF, Lange BJ. Infections with viridans group streptococci in children with cancer. Pediatr Blood Cancer. 2007;49:774–780
  33. Graber CJ, de Almeida KN, Atkinson JC, Javaheri D, Fukuda CD, Gill VJ, et al. Dental health and viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2001;27:537–542
  34. Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002;34:1524–1529
  35. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14:1201–1207
  36. Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents. 2000;14:129–135
  37. Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000;31:1126–1130
  38. Richard P, Amador Del Valle G, Moreau P, Milpied N, Felice MP, Daeschler T, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet. 1995;345:1607–1609
  39. Martino R, Manteiga R, Sanchez I, Brunet S, Sureda A, Badell I, et al. Viridans streptococcal shock syndrome during bone marrow transplantation. Acta Haematol. 1995;94:69–73
  40. Sandlund JT, Howard SC, Hijiya N, Pui CH, Shenep JL, Adderson EE. Myositis complicating viridans streptococcal sepsis in childhood leukemia. Pediatr Blood Cancer. 2005;44:277–279
  41. Leblanc T, Leverger G, Arlet G, Siguret V, Schaison G. [Frequency and severity of systemic infections caused by Streptococcus mitis and sanguis II in neutropenic children]. Pathol Biol. 1989;37:459–464
  42. Villablanca JG, Steiner M, Kersey J, Ramsay NK, Ferrieri P, Haake R, et al. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant. 1990;5:387–393
  43. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–259
  44. Gassas A, Grant R, Richardson S, Dupuis LL, Doyle J, Allen U, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 2004;22:1222–1227
  45. Singh TN, Devi KM, Devi KS. Ecthyma gangrenosum: a rare cutaneous manifestation caused by pseudomonas aeruginosa without bacteraemia in a leukaemic patient—a case report. Ind J Med Microbiol. 2005;23:262–263
  46. Kapil A, Gulati S, Goel V, Kumar L, Krishnan R, Kochupillai V. Outbreak of nosocomial Acinetobacter baumannii bacteremia in a high risk ward. Med Oncol (Northwood, London, England). 1998;15:270–274
  47. Adler A, Yaniv I, Steinberg R, Solter E, Samra Z, Stein J, et al. Infectious complications of implantable ports and Hickman catheters in paediatric haematology-oncology patients. J Hosp Infect. 2006;62:358–365
  48. Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis. 2004;39(Suppl 1):S44–S48
  49. Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol. 2008;25:291–299
  50. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrobial Chemother. 2006;57:176–189
  51. Rolston KV, Bodey GP. Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrobial Chemother. 2006;58:478
  52. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol. 2006;23:177–186
  53. Ariffin H, Ai CL, Lee CL, Abdullah WA. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health. 2006;42:781–784
  54. Mustafa MM, Carlson L, Tkaczewski I, McCracken GH, Buchanan GR. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2001;20:362–369
  55. Castagnola E, Haupt R, Micozzi A, Caviglia I, Testi AM, Giona F, et al. Differences in the proportions of fluoroquinolone-resistant gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clin Microbiol Infect. 2005;11:505–507
  56. Kurt B, Flynn P, Shenep JL, Pounds S, Lensing S, Ribeiro RC, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113:376–382
  57. Paul M, Gafter-Gvili A, Leibovici L, Bishara J, Levy I, Yaniv I, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J. 2007;9:424–429
  58. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrobial Agents Chemother. 1997;41:1127–1133
  59. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG, Levine AS, Deisseroth AB, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med. 1979;67:194–200
  60. Mullen CA. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J. 2003;22:1138–1142
  61. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV, et al. Antimicrobial therapy of unexplained fever in neutropenic patients—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003;82(Suppl 2):S105–S117
  62. Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clin Microbiol Infect. 2006;12:606–620
  63. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602–1609
  64. Paulino AF, Kenney R, Forman EN, Medeiros LJ. Typhlitis in a patient with acute lymphoblastic leukemia prior to the administration of chemotherapy. Am J Pediatr Hematol Oncol. 1994;16:348–351
  65. Otaibi AA, Barker C, Anderson R, Sigalet DL. Neutropenic enterocolitis (typhlitis) after pediatric bone marrow transplant. J Pediatr Surg. 2002;37:770–772
  66. Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group study CCG-59704. Ann Oncol. 2002;13(Suppl 1):107–111
  67. McCarville MB, Adelman CS, Li C, Xiong X, Furman WL, Razzouk BI, et al. Typhlitis in childhood cancer. Cancer. 2005;104:380–387
  68. Sloas MM, Flynn PM, Kaste SC, Patrick CC. Typhlitis in children with cancer: a 30-year experience. Clin Infect Dis. 1993;17:484–490
  69. Wade JC. Viral infections in patients with hematological malignancies. Hematol Am Soc Hematol Educ Program. 2006;368–374
  70. Christensen MS, Nielsen LP, Hasle H. Few but severe viral infections in children with cancer: a prospective RT-PCR and PCR-based 12-month study. Pediatr Blood Cancer. 2005;45:945–951
  71. Koskenvuo M, Mottonen M, Rahiala J, Saarinen-Pihkala UM, Riikonen P, Waris M, et al. Respiratory viral infections in children with leukemia. Pediatr Infect Dis J. 2008;27:974–980
  72. Mendoza Sanchez MC, Ruiz-Contreras J, Vivanco JL, Fernandez-Carrion F, Baro Fernandez M, Ramos JT, et al. Respiratory virus infections in children with cancer or HIV infection. J Pediatr Hematol Oncol. 2006;28:154–159
  73. Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, et al. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51:784–786
  74. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics. 2008;121:235–243
  75. Porter CC, Edwards KM, Zhu Y, Frangoul H. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004;42:36–40
  76. Porter CC, Poehling KA, Hamilton R, Frangoul H, Cooper WO. Influenza immunization practices among pediatric oncologists. J Pediatr Hematol Oncol. 2003;25:134–138
  77. Report of the Committee on Influenza. In:  Pickering L,  Baker C,  Overturf G,  Prober C editor. AAP Red Book. Elk Grove Village, IL: American Academy of Pediatrics; 2006;p. 401–411
  78. Hough R, Chetwood A, Sinfield R, Welch J, Vora A. Fatal adenovirus hepatitis during standard chemotherapy for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2005;27:67–72
  79. Hill G, Chauvenet AR, Lovato J, McLean TW. Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics. 2005;116:e525–e529
  80. Report of the Committee on Varicella. In:  Pickering L,  Baker C,  Overturf G,  Prober C editor. AAP Red Book. Elk Grove Village, IL: American Academy of Pediatrics; 2006;p. 711–725
  81. Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004;8:259–270
  82. Report of the Committee on Cytomegalovirus. In:  Pickering L,  Baker C,  Overturf G,  Prober C editor. AAP Red Book. Elk Grove Village, IL: American Academy of Pediatrics; 2006;p. 273–277
  83. Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematol Am Soc Hematol Educ Program. 2006;375–380
  84. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106:2645–2651
  85. Lindblom A, Heyman M, Gustafsson I, Norbeck O, Kaldensjo T, Vernby A, et al. Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis. 2008;46:528–536
  86. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol. 2005;27:135–140
  87. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–1554
  88. Grigull L, Beier R, Schrauder A, Kirschner P, Loening L, Jack T, et al. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses. 2003;46:441–446
  89. Lehrnbecher T, Kaiser J, Varwig D, Ritter J, Groll AH, Creutzig U, et al. Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93. Eur J Clin Microbiol Infect Dis. 2007;26:735–738
  90. Bow EJ. Of yeasts and hyphae: a hematologist's approach to antifungal therapy. Hematol Am Soc Hematol Educ Program. 2006;361–367
  91. Zaoutis TE, Foraker E, McGowan KL, Mortensen J, Campos J, Walsh TJ, et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis. 2005;52:295–298
  92. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am. 2006;20:663–678
  93. Gozdasoglu S, Ertem M, Buyukkececi Z, Yavuzdemir S, Bengisun S, Ozenci H, et al. Fungal colonization and infection in children with acute leukemia and lymphoma during induction therapy. Med Pediatr Oncol. 1999;32:344–348
  94. Alberth M, Majoros L, Kovalecz G, Borbas E, Szegedi I, Marton IJ, et al. Significance of oral Candida infections in children with cancer. Pathol Oncol Res. 2006;12:237–241
  95. Sallah S, Wan JY, Nguyen NP, Vos P, Sigounas G. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. Cancer. 2001;92:1349–1353
  96. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J. 2004;23:635–641
  97. Gorschluter M, Mey U, Strehl J, Schmitz V, Rabe C, Pauls K, et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis. 2006;6:35
  98. Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr. 2002;161:563–574
  99. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711–e716
  100. Hayden R, Pounds S, Knapp K, Petraitiene R, Schaufele RL, Sein T, et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J. 2008;27:815–819
  101. Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007;48:28–34
  102. Wirth F, Perry R, Eskenazi A, Schwalbe R, Kao G. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. J Am Acad Dermatol. 1997;36:336–341
  103. Zaoutis TE, Roilides E, Chiou CC, Buchanan WL, Knudsen TA, Sarkisova TA, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007;26:723–727

PII: S0037-1963(09)00065-1

doi: 10.1053/j.seminhematol.2009.03.010

Seminars in Hematology
Volume 46, Issue 3 , Pages 313-324 , July 2009

Article Tools